Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Prevalence of different bone status in our HypoPT patientsHypoPT casesDXA evaluationNo. cases in which DXA analysis was available* (%)Osteoporosis (no. cases) (%)Osteopenia (no. cases) (%)Normal BMD (no. cases) (%)Increased BMD (no. cases) (%)Total HypoPT cases > 19 years (n = 453) 162 (35.8)28 (17.3)Mean age 62.3 ± 12.2 years (median 65.0; range 28 to 78)50 (30.9)Mean age 56.0 ± 14.0 years (median 60.5; range 20 to 81)60 (37.0.)Mean age 49.6 ± 14.4 years (median 52.0; range 20 to 75)24 (14.8)Mena age 55.0 ± 16.7 years (median 55.0; range 24 to 80)Total HypoPT cases ≤ 19 years (n = 56)11 (19.6)Not applicable2 (18.2)Aged 6 and 10 years7 (63.6)Mean age 12.9 ± 6.8 years (median 14.0; range 4 to 19) 2 (18.2.)Aged 17 and 19 yearsHypoPT cases 20 to 50 years (n = 183)51 (27.9)4 (7.8)Mean age 38.3 ± 7.3 years (median 40.5; range 28 to 44)14 (27.5)Mean age 37.8 ± 10.8 years (median 41.0; range 20 to 50)27 (52.9)Mean age 36.0 ± 8.2 years (median 36.0; range 20 to 49)6 (11.8)Mean age 37.5 ± 7.4 years (median 38.0; range 24 to 46)HypoPT cases > 50 years (n = 270)111 (41.1)24 (21.6)Mean age 66.3 ± 7.2 years (median 68.0; range 54 to 78)36 (32.4)Mean age 63.1 ± 6.9 years (median 63.5; range 51 to 81)33 (29.7)Mean age 60.7 ± 6.6 years (median 61.0; range 51 to 75)18 (16.2)Mean age 60.8 ± 8.0 years (median 59.5; range 51 to 75)Total HypoPT women > 19 years (n = 362)135 (37.3)25 (18.5)Mean age 64.3 ± 10.1 years (median 68.0; range 38 to 78)46 (34.1)Mean age 56.1 ± 13.3 years (median 59.5; range 23 to 81)47 (34.8)Mean age 52.0 ± 12.6 years (median 53.0; range 27 to 75) 17 (12.6)Mean age 55.5 ± 18.9 years (median 55.0; range 24 to 80)HypoPT women 20 to 50 years/premenopausal (n = 140)38 (27.1)2 (5.3)Aged 38 and 43 years13 (34.2)Mean age 39.2 ± 9.9 years (median 43.0; range 23 to 50)19(50.0)Mean age 39.2 ± 7.0 years (median 41.0; range 27 to 49)4 (10.5)Mean age 36.0 ± 9.1 years (median 37.0; range 24 to 46) HypoPT women > 50 years/postmenopausal (n = 222) 97 (43.7)23 (23.7)Mean age 66.4 ± 7.3 years (median 68.0; range 54 to 78)33 (34.0) Mean age 62.8 ± 7.1 years (median 62.0; range 51 to 81) 28 (28.9) Mean age 60.7 ± 6.7 years (median 61.0; range 51 to 75) 13 (13.4) Mean age 61.5 ± 8.8 years (median 60.0; range 51 to 80) Total HypoPT men > 19 years (n = 91) 27 (29.7)3 (11.1)Mean age 45.7 ± 18.6 years (median 44.0; range 28 to 65) 4 (14.8) Mean age 55.3 ± 23.6 years (median 65.5; range 20 to 70) 13 (48.2) Mean age 40.9 ± 17.5 years (median 34.0; range 20 to 68) 7 (25.9) Mean age 53.7 + 21.2 years (median 55.0; range 39 to 67) HypoPT men 20 to 50 years (n = 43) 13 (30.2) 2 (15.4)Aged 28 and 44 years 1 (7.7)Aged 20 years 8 (61.5)Mean age 28.4 ± 5.2 years (median 27.5; range 20 to 37) 2 (15.4)Aged 39 and 42 years HypoPT men > 50 years (n = 48) 14 (29.2) 1 (7.1)Aged 65 years 3 (21.4)Mean age 67.0 ± 2.6 years (median 66.0; range 65 to 70) 5 (35.7)Mean age 61.0 ± 7.0 years (median 64.0; range 53 to 68) 5 (35.7)Mean age 59.0 ± 5.7 years (median 56.0; range 54 to 67) Post-surgical HypoPT cases (n = 363) 127 (35.0) 24 (18.9)Mean age 65.4 ± 8.6 years (median 68.0; range 43 to 78) 44 (34.6)Mean age 56.2 ± 13.2 years (median 59.5; range 23 to 81) 44 (34.6)Mean age 53.3 ± 12.6 years (median 54.0; range 20 to 75) 15 (11.8)Mean age 56.5 ± 13.1 years (median 55.0; range 37 to 80) Idiopathic HypoPT cases (n = 78) 29 (37.2) 1 (3.4)Aged 65 years 4 (13.8)Mean age 60.0 ± 14.2 years (median 65.5; range 39 to 70) 14 (48.3)Mean age 34.8 ± 17.0 years (median 29.5; range 11 to 68) 10 (34.5)Mean age 49.2 ± 16.1 years (median 54.5; range 19 to 67) Genetically-determined HypoPT cases (n = 64) 14 (21.9) 0 8 (57.1)Mean age 18.1 ± 21.1 years (median 12.0; range 4 to 68) 5 (35.7)Mean age 38.0 ± 12.2 years (median 33.0; range 26 to 53) 1 (7.1)Aged 17 years HypoPT cases from other causes (n = 4) 3 (75) 3 (100)Mean age 36.7 ± 8.1 years (median 38.0; range 28 to 44) 0 0 0 Total hypoPT cases with normal values of calciuria (≤ 300 mg/24 h) (n = 160) 87 (54.4) 11 (12.6)Mean age 64.7 ± 12.3 years (median 71.0; range 38 to 78) 28 (32.2)Mean age 52.5 ± 16.9 years (median 60.0; range 6 to 67) 32 (36.8)Mean age 48.8 ± 16.2 years (median 50.0; range 19 to 75) 16 (18.4)Mean age 55.1 ± 12.1 years (median 55.0; range 24 to 71) Total hypoPT cases with hypercalciuria (> 300 mg/24 h) (n = 71) 33 (46.5) 7 (21.2) Mean age 60.1 ± 12.3 years (median 68.0; range 43 to 72) 8 (24.2) Mean age 63.9 ± 11.3 years (median 61.5; range 50 to 81) 11 (33.3) Mean age 49.3 ± 14.2 years (median 55.0; range 27 to 66) 7 (21.2) Mean age 42.7 ± 20.4 years (median 39.0; range 17 to 68)HypoPT cases > 19 years with normal values of calciuria (≤ 300 mg/24 h) (n = 151) 83 (55.0) 11 (13.3) Mean age 64.7 ± 12.3 years (median 71.0; range 38 to 78) 26 (31.3) Mean age 55.9 ± 11.8 years (median 61.5; range 23 to 67) 30 (36.1) Mean age 50.8 ± 14.7 years (median 51.0; range 26 to 75) 16 (19.3) Mean age 55.1 ± 12.1 years (median 55.0; range 24 to 71) HypoPT cases aged 20 to 50 years with normal values of calciuria (≤ 300 mg/24 h) (n = 65) 26 (40.0) 1 (3.8) Aged 38 years 8 (30.8) Mean age 41.0 ± 8.8 years (median 44.0; range 23 to 49) 14 (53.8) Mean age 37.7 ± 8.4 years (median 39.0; range 26 to 49) 3 (11.5) Mean age 35.7 ± 11.1 years (median 37.0; range 24 to 46) HypoPT cases > 50 years years with normal values of calciuria (≤ 300 mg/24 h) (n = 86) 57 (66.3) 10 (17.5) Mean age 67.4 ± 9.0 years (median 71.0; range 56 to 78) 18 (31.6) Mean age 62.5 ± 4.6 years (median 64.5; range 52 to 67) 16 (28.1) Mean age 62.3 ± 7.6 years (median 64.5; range 51 to 75) 13 (22.8) Mean age 59.5 ± 6.8 years (median 59.0; range 51 to 71) HypoPT cases > 19 years with hypercalciuria (> 300 mg/24 h) (n = 65) 31 (47.7) 7 (22.6) Mean age 60.1 ± 12.3 years (median 68.0; range 43 to 72) 8 (26.7) Mean age 63.9 ± 11.3 years (median 61.5; range 50 to 81) 11 (35.5) Mean age 49.3 ± 14.2 years (median 55.0; range 27 to 66) 5 (16.1) Mean age 52.6 ± 14.0 years (median 56.0; range 37 to 68)HypoPT cases aged 20 to 50 years with hypercalciuria (> 300 mg/24 h) (n = 27) 9 (33.3) 2 (22.2) Aged 43 and 44 years 1 (11.1) Aged 50 years 4 (44.4) Mean age 32.8 ± 6.9 years (median 31.0; range 27 to 42) 2 (22.2) Aged 37 and 39 yearsHypoPT cases > 50 years with hypercalciuria (> 300 mg/24 h) (n = 38) 22 (57.9) 5 (22.7) Mean age 63.9 ± 5.7 years (median 68.0; range 57 to 72) 7 (31.8) Mean age 65.9 ± 10.6 years (median 62.0; range 51 to 81) 7 (31.8) Mean age 58.7 ± 5.1 years (median 57.0; range 52 to 66) 3 (13.6) Mean age 62.3 ± 6.0 years (median 63.0; range 56 to 68) Total hypoPT cases with normal values of phosphaturia (≥ 400 mg/24 h) (n = 101) 60 (59.4) 4 (6.7) Mean age 56.5 ± 1.6 years (median 56.0; range 43 to 71) 14 (23.3) Mean age 55.9 ± 12.9 years (median 57.0; range 34 to 81) 29 (48.3) Mean age 52.2 ± 14.1 years (median 52.0; range 26 to 75) 13 (21.7) Mean age 44.1 ± 16.2 years (median 53.0; range 17 to 63) Total hypoPT cases with hypophosphaturia (< 400 mg/24 h) (n = 61) 34 (55.7) 6 (17.6) Mean age 62.5 ± 15.3 years (median 65.5; range 38 to 74) 12 (35.3) Mean age 57.7 ± 14.5 years (median 62.0; range 23 to 78) 9 (26.5) Mean age 41.7 ± 18.6 years (median 41.0; range 19 to 68) 7 (20.6) Mean age 59.6 ± 9.8 years (median 60.0; range 46 to 71) HypoPT cases > 19 years with normal values of phosphaturia (≥ 400 mg/24 h) (n = 93) 58 (62.4) 4 (6.9) Mean age 56.5 ± 15.1 years (median 56.0; range 43 to 71) 14 (24.1) Mean age 55.9 ± 12.9 years (median 57.0; range 34 to 81) 29 (50.0) Mean age 52.2 ± 14.1 years (median 52.0; range 26 to 75) 11 (19.0) Mean age 48.8 ± 12.5 years (median 54.0; range 24 to 63) HypoPT cases aged 20 to 50 years with normal values of phosphaturia (≥ 400 mg/24 h) (n = 43) 23 (53.5) 2 (8.7) Aged 43 and 44 years 5 (21.7) Mean age 42.6 ± 6.3 years (median 43.0; range 34 to 50) 12 (52.2) Mean age 38.2 ± 8.2 years (median 39.5; range 26 to 49) 4 (17.4) Mean age 34.3 ± 6.9 years (median 37.0; range 24 to 39) HypoPT cases > 50 years with normal values of phosphaturia (≥ 400 mg/24 h) (n = 50) 35 (70.0) 2 (5.7) Aged 68 and 71 years 9 (25.7) Mean age 63.2 ± 8.9 years (median 62.0; range 51 to 81) 17 (48.6) Mean age 62.1 ± 7.0 years (median 64.0; range 51 to 75) 7 (20.0) Mean age 57.1 ± 3.6 years (median 56.0; range 53 to 63) HypoPT cases > 19 years with hypophosphaturia (< 400 mg/24 h) (n = 57) 32 (56.1) 6 (18.7) Mean age 62.5 ± 15.3 years (median 65.5; range 38 to 78) 12 (37.5) Mean age 57.7 ± 14.5 years (median 62.0; range 23 to 78) 7 (21.9) Mean age 48.1 ± 15.6 years (median 45.0; range 28 to 68) 7 (21.9) Mean age 59.6 ± 9.8 years (median 59.8; range 46 to 71) HypoPT cases aged 20 to 50 years with hypophosphaturia (< 400 mg/24 h) (n = 25) 10 (40.0) 1 (10.0) Aged 38 years 4 (40.0) Mean age 41.3 ± 12.3 years (median 46.5; range 23 to 49) 4 (40.0) Mean age 36.8 ± 7.7 years (median 37.0; range 28 to 45) 1 (10.0) Aged 46 yearsHypoPT cases > 50 years with hypophosphaturia (< 400 mg/24 h) (n = 32) 22 (68.8) 5 (22.7) Mean age 67.4 ± 10.7 years (median 73.0; range 54 to 78) 8 (36.4) Mean age 65.9 ± 5.8 years (median 65.5; range 59 to 78) 3 (13.6) Mean age 63.3 ± 5.7 years (median 65.0; range 57 to 68) 6 (27.3) Mean age 61.8 ± 8.5 years (median 61.8; range 51 to 71) Total hypoPT cases with 25(OH)-vitamin D deficiency/insufficiency (< 30 ng/ml) (n = 124) 52 (41.9) 12 (23.1) Mean age 60.0 ± 13.2 years (median 60.0; range 68 to 72) 14 (26.9) Mean age 57.7 ± 16.1 years (median 62.0; range 10 to 78) 16 (30.8) Mean age 40.0 ± 21.2 years (median 33.5; range 4 to 75) 10 (19.2) Mean age 59.5 ± 9.9 years (median 57.5; range 46 to 80) Total hypoPT cases with normal levels of 25(OH)-vitamin D (≥ 30 ng/ml) (n = 98) 40 (40.8) 3 (7.5) Mean age 69.7 ± 2.1 years (median 69.0; range 68 to 72) 14 (35.0) Mean age 56.0 ± 12.8 years (median 57.5; range 23 to 77) 18 (45.0) Mean age 47.0 ± 14.7 years (median 48.0; range 19 to 68) 5 (12.5) Mean age 48.8 ± 15.8 years (median 39.0; range 37 to 71) HypoPT cases > 19 years with 25(OH)-vitamin D deficiency/insufficiency (< 30 ng/ml) (n = 113) 48 (42.5) 12 (25.0) Mean age 60.0 ± 13.2 years (median 60.0; range 38 to 78) 13 (27.1) Mean age 61.4 ± 8.7 years (median 63.0; range 48 to 78) 13 (27.1) Mean age 46.6 ± 17.4 years (median 53.0; range 26 to 75) 10 (20.8) Mean age 59.5 ± 9.9 years (median 57.5; range 46 to 80) HypoPT cases aged 20 to 50 years with 25(OH)-vitamin D deficiency/insufficiency (< 30 ng/ml) (n = 46) 12 (26.1) 3 (25.0) Mean age 41.7 ± 3.2 years (median 43.0; range 38 to 44) 2 (16.7) Aged 48 and 49 years 6 (50.0) Mean age 29.8 ± 3.3 years (median 29.5; range 26 to 34) 1 (8.3) Aged 46 yearsHypoPT cases > 50 years with 25(OH)-vitamin D deficiency/insufficiency (< 30 ng/ml) (n = 67) 36 (53.7) 9 (25.0) Mean age 66.1 ± 8.4 years (median 68.0; range 54 to 78) 11 (30.6) Mean age 63.7 ± 7.1 years (median 65.0; range 51 to 78) 7 (19.4) Mean age 61.0 ± 8.4 years (median 57.0; range 53 to 75) 9 (25.0) Mean age 61.0 ± 9.2 years (median 59.0; range 53 to 80) HypoPT cases > 19 years with normal levels of 25(OH)-vitamin D (≥ 30 ng/ml) (n = 92)38 (41.3) 3 (7.9) Mean age 69.7 ± 2.1 years (median 69.0; range 68 to 72) 14 (38.9) Mean age 56.0 ± 12.8 years (median 57.5; range 23 to 77) 16 (42.1) Mean age 50.5 ± 11.3 years (median 48.5; range 33 to 68) 5 (13.1) Mean age 48.8 ± 15.8 years (median 39.0; range 37 to 71) HypoPT cases aged 20 to 50 years with normal levels of 25(OH)-vitamin D (≥ 30 ng/ml) (n = 44)16 (36.4) 0 4 (25.0) Mean age 41.5 ± 12.5 years (median 46.5; range 23 to 50) 9 (56.3) Mean age 42.4 ± 6.5 years (median 45.0; range 33 to 49) 3 (18.7) Mean age 37.7 ± 1.2 years (median 37.0; range 37 to 39) HypoPT cases > 50 years with normal levels of 25(OH)-vitamin D (≥ 30 ng/ml) (n = 48)22 (41.7) 3 (13.6) Mean age 69.7 ± 2.1 years (median 69.0; range 68 to 72) 10 (45.5) Mean age 61.8 ± 7.2 years (median 62.0; range 52 to 77) 7 (31.8) Mean age 60.9 ± 6.2 years (median 64.0; range 51 to 68) 2 (9.1) Aged 60 and 71 years* = Availability of at least one T-score value (or Z-score value for individuals aged 20 to 50 years, and for children and adolescents) in one of the four bone sites (lumbar spine, femur neck, total femur, and distal radius)Numbers in parentheses, in columns 2 to 6, indicate a percentage value% of osteoporosis, osteopenia, normal BMD, and increased BMD were calculated respect to the number of HypoPT cases with available DXA evaluation.
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
In this cross-sectional study, we retrospectively analyzed bone status in 162 adult, and 11 children and adolescent HypoPT cases, based to their sex, age, HypoPT etiology, urinary excretion of calcium and phosphate, and serum level of 25(OH)-vitamin D.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Bone status in patients with chronic hypoparathyroidism: results from the Italian HypoparaNET database
Cross-sectional study · Aging Clinical and Experimental Research · 2025
Original publication title
Bone status in patients with chronic hypoparathyroidism: results from the Italian HypoparaNET database
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Investigating bone status in a cohort of Italian HypoPT patients from the HypoparaNET database.
Source: AimAbstract: What methods does the paper describe?
In this cross-sectional study, we retrospectively analyzed bone status in 162 adult, and 11 children and adolescent HypoPT cases, based to their sex, age, HypoPT etiology, urinary excretion of calcium and phosphate, and serum level of 25(OH)-vitamin D.
Source: MethodsAbstract: Discussion
Results from this study suggest the importance of a regular follow-up of bone health in HypoPT, especially in postmenopausal women and young patients with a genetic form of HypoPT.
Source: DiscussionAbstract: Results
Overall prevalence of osteoporosis in adult HypoPT patients was found to be slightly lower to that of the general population (17.3% vs 18.3%), increasing with ageing and being more frequent in postmenopausal women. Data from our HypoPT cohort confirmed that ageing and female sex are independent risk factors for osteoporosis, even among individuals with HypoPT.
Source: ResultsAbstract: Conclusions
Medical therapies aim at restoring a balanced bone turnover and preventing bone tissue loss could be indicated in HypoPT cases with reduced bone mass to grant a better bone health at any age.
Source: ConclusionsAuthors’ abstract
Background
Chronic hypoparathyroidism (HypoPT) is a rare endocrine condition, having variable etiology, characterized by low parathyroid hormone levels, leading to reduced calcium levels and increased phosphorus values in the blood. Bone health is an important clinical aspect to be considered in patients with HypoPT, whose skeleton is exposed both to the HypoPT-induced alteration of bone mass and microarchitecture, and to the natural occurrence and progression of bone mass loss due to menopause and ageing.
Aim
Investigating bone status in a cohort of Italian HypoPT patients from the HypoparaNET database.
Methods
In this cross-sectional study, we retrospectively analyzed bone status in 162 adult, and 11 children and adolescent HypoPT cases, based to their sex, age, HypoPT etiology, urinary excretion of calcium and phosphate, and serum level of 25(OH)-vitamin D.
Results
Overall prevalence of osteoporosis in adult HypoPT patients was found to be slightly lower to that of the general population (17.3% vs 18.3%), increasing with ageing and being more frequent in postmenopausal women. Data from our HypoPT cohort confirmed that ageing and female sex are independent risk factors for osteoporosis, even among individuals with HypoPT.
Discussion
Results from this study suggest the importance of a regular follow-up of bone health in HypoPT, especially in postmenopausal women and young patients with a genetic form of HypoPT.
Conclusions
Medical therapies aim at restoring a balanced bone turnover and preventing bone tissue loss could be indicated in HypoPT cases with reduced bone mass to grant a better bone health at any age.
Publication and source details
Original title: Bone status in patients with chronic hypoparathyroidism: results from the Italian HypoparaNET database
Francesca Marini; Francesca Giusti; Blandine Weiss; Michel Ovize; Salvatore Benvenga; Filomena Cetani; Annamaria Colao; Sabrina Corbetta; Marta Bondanelli; Maurizio Iacobone; Andrea Lenzi; Giovanna Mantovani; Rosaria Maddalena Ruggeri; Luigi di Filippo; Andrea Giustina; Dalal S. Ali; Aliya A. Khan; Gemma Marcucci; Maria Luisa Brandi; on the behalf of the HypoparaNet team
Aging Clinical and Experimental Research · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Amolyt Pharma (France)Università degli Studi di FirenzeOpen access funding provided by Università degli Studi di Firenze within the CRUI-CARE Agreement.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T01:23:16.423849+00:00
DOI: 10.1007/s40520-025-03139-9 · PMC12287157